8USM image
Entry Detail
PDB ID:
8USM
Keywords:
Title:
FmlH Lectin Domain UTI89 - AM4085
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2023-10-27
Release Date:
2024-02-14
Method Details:
Experimental Method:
Resolution:
1.63 Å
R-Value Free:
0.22
R-Value Work:
0.20
Space Group:
P 21 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Fimbrial protein (Fragment)
Chain IDs:A, B
Chain Length:166
Number of Molecules:2
Biological Source:Escherichia coli
Ligand Molecules
Primary Citation
Discovery of Orally Bioavailable FmlH Lectin Antagonists as Treatment for Urinary Tract Infections.
J.Med.Chem. 67 3668 3678 (2024)
PMID: 38308631 DOI: 10.1021/acs.jmedchem.3c02128

Abstact

FmlH, a bacterial adhesin of uropathogenic Escherichia coli (UPEC), has been shown to provide a fitness advantage in colonizing the bladder during chronic urinary tract infections (UTIs). Previously reported ortho-biphenyl glycosides based on βGal and βGalNAc have excellent binding affinity to FmlH and potently block binding to its natural carbohydrate receptor, but they lack oral bioavailability. In this paper, we outline studies where we have optimized compounds for improved pharmacokinetics, leading to the discovery of novel analogues with good oral bioavailability. We synthesized galactosides with the anomeric O-linker replaced with more stable S- and C-linked linkers. We also investigated modifications to the GalNAc sugar and modifications to the biphenyl aglycone. We identified GalNAc 69 with an IC50 of 0.19 μM against FmlH and 53% oral bioavailability in mice. We also obtained a FimlH-bound X-ray structure of lead compound 69 (AM4085) which has potential as a new antivirulence therapeutic for UTIs.

Legend

Protein

Chemical

Disease

Primary Citation of related structures